CCDM practice question 20 of 25

An astute monitor discovers that a site is using nebulized albuterol rather than the inhaler provided in the study screening kit for the albuterol challenge. Which is the best response from the Data Manager?

Full set: 150 questions
Answer options
A: No response is needed, the problem does not impact data
B: Contact the Ethics Committee
C: Update the CRF Completion Guidelines and notify all sites of the update
D: Query the site to enter a Protocol Violation Correct answer
Correct Answer:
D. Query the site to enter a Protocol Violation
Explanation

The Data Manager's primary responsibility is to ensure the integrity, accuracy, and quality of the clinical trial data. The use of a nebulizer instead of the protocol-specified inhaler constitutes a significant protocol violation that directly impacts the validity of the data collected from the albuterol challenge. The most appropriate and direct response from the Data Manager is to issue a data query to the site. This action prompts the site to formally document the event as a protocol violation within the clinical database, ensuring that the deviation is officially recorded, tracked, and available for review during data analysis and regulatory reporting.

Why Incorrect

A. This is incorrect because the method of drug administration critically affects bioavailability and patient response, thus severely impacting data integrity and comparability.
B. Reporting to the Ethics Committee/IRB is the responsibility of the Investigator or Sponsor, not the primary action of the Data Manager.
C. The problem is a failure to follow the protocol, not an issue with the CRF Completion Guidelines; updating the guidelines is an inappropriate response.

References

1. Society for Clinical Data Management (SCDM). (2023). Good Clinical Data Management Practices (GCDMP). Section 6.5, "Data Review," and Section 6.6, "Query Management," outline the Data Manager's responsibility to review data for protocol compliance and to issue queries to resolve discrepancies and ensure proper documentation of events like protocol deviations.

2. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2016). Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). Section 5.1.1 emphasizes the sponsor's responsibility for implementing and maintaining quality assurance systems to ensure trials are conducted and data are generated and documented in compliance with the protocol. The Data Manager's query is a key component of this quality system.

3. Krishnankutty, B., Bellary, S., Kumar, N. B. R., & Moodahadu, L. S. (2012). Data management in clinical research: An overview. Indian journal of pharmacology, 44(2), 168–172. https://doi.org/10.4103/0253-7613.93842. This article describes the data validation process, which includes "consistency checks" (p. 170) to identify data that is not consistent with the protocol. The standard process to resolve such findings is the issuance of a data query form to the investigator.

Scroll to Top